Increasing Use Of Interferon Gamma Release Assays Among Children ≥2 Years of Age in a Setting With Low Tuberculosis Prevalence.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
entrez:
14
11
2022
pubmed:
15
11
2022
medline:
18
11
2022
Statut:
ppublish
Résumé
US guidelines recommend interferon gamma release assays (IGRAs) for diagnosis of tuberculosis infection in children. In this retrospective cohort study, IGRA use in children 2-17 years of age increased substantially between 2015 and 2021. Testing in inpatient/subspecialty settings (vs. primary care), public (vs. private) insurance, lower age and non-English preferred language were associated with increased odds of receiving an IGRA.
Identifiants
pubmed: 36375104
doi: 10.1097/INF.0000000000003685
pii: 00006454-202212000-00026
pmc: PMC10332931
mid: NIHMS1914948
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e534-e537Subventions
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Organisme : AHRQ HHS
ID : T32 HS000063
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
J.I.C. was supported by Agency for Healthcare Research and Quality grant number T32 HS000063 as part of the Harvard-wide Pediatric Health Services Research Fellowship Program. J.E.H. is a consultant for Merck. The other authors have no conflicts of interest to disclose.
Références
Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54:49–55.
American Academy of Pediatrics. Tuberculosis. Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. In: Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: pp. 829–853.
American Academy of Pediatrics. Tuberculosis. Kemberlin DW, Barnett ED, Lyfield R, Sawyer MH, eds. In: Red Book: 2021 Report of the Committee on Infectious Disease. Itisca, IL: American Academy of Pediatrics: 2021. pp 786–814.
Cruz AT, Reichman LB. The case for retiring the tuberculin skin test. Pediatrics. 2019;143:e20183327.
Ahmed A, Feng PI, Gaensbauer JT, et al.; Tuberculosis Epidemiologic Studies Consortium. Interferon-γ release assays in children <15 years of age. Pediatrics. 2020;145:e20191930.
Starke JR. Tuberculin skin test versus the interferon-γ release assays: out with the old, in with the new. Pediatrics. 2020;145:e20193021.
Goetzinger F, Burkhardt I, Villanueva P, et al. Interferon-gamma release assays have suboptimal sensitivity in both latent and active tuberculosis. Int J Tuberc Lung Dis. 2019;23:766–767.
Bonnewell JP, Farrow L, Dicks KV, et al. Geographic analysis of latent tuberculosis screening: a health system approach. PLoS One. 2020;15:e0242055.
Edozie RK, Lewis B, Lo S, et al. Changing Faces of Greater Boston. 2019. Available at: https://wwwbostonindicatorsorg/-/media/indicators/boston-indicators-reports/report-files/changing-faces-2019/indicators-changing-facesf2webpdf . Accessed October 26, 2021.
McQuaid CF, Vassall A, Cohen T, et al. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis. 2021;25:436–446.
Mandalakas AM, Highsmith HY, Harris NM, et al. T-SPOT.TB performance in routine pediatric practice in a low TB burden setting. Pediatr Infect Dis J. 2018;37:292–297.
Deuffic-Burban S, Atsou K, Viget N, et al. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tubercu Lung Dis. 2010;14:471–481.